{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05619744",
            "orgStudyIdInfo": {
                "id": "BP44382"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-506354-20-00",
                    "type": "OTHER",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas",
            "officialTitle": "An Open-Label, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7616789 in Participants With Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-safety-tolerability-pharmacokinetics-pharmacodynamics-and-preliminary-anti-tumor-activity-of-in-advanced-small-cell-lung-cancer-and-other-neuroendocrine-carcinomas"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-01-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-11-09",
            "studyFirstSubmitQcDate": "2022-11-09",
            "studyFirstPostDateStruct": {
                "date": "2022-11-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Hoffmann-La Roche",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study."
        },
        "conditionsModule": {
            "conditions": [
                "Small Cell Lung Cancer",
                "Neuroendocrine Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 168,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: RO7616789 QW: Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a fixed dose of RO7616789 intravenously once weekly (QW) per dose level on Day 1, 8, and 15 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.",
                    "interventionNames": [
                        "Drug: RO7616789",
                        "Drug: Tocilizumab"
                    ]
                },
                {
                    "label": "Part 2: RO7616789 Q3W: Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a fixed dose of RO7616789, at a dose determined in Part 1, intravenously once every 3 weeks (Q3W) on Day 1 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.",
                    "interventionNames": [
                        "Drug: RO7616789",
                        "Drug: Tocilizumab"
                    ]
                },
                {
                    "label": "Part 3: Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Based on emerging data from Part 1 and 2, one or more dosing regimens will be further investigated in Part 3.",
                    "interventionNames": [
                        "Drug: RO7616789",
                        "Drug: Tocilizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "RO7616789",
                    "description": "RO7616789 solution for infusion will be administered intravenously at a dose and per schedule as specified for the respective part.",
                    "armGroupLabels": [
                        "Part 1: RO7616789 QW: Dose Escalation",
                        "Part 2: RO7616789 Q3W: Dose Escalation",
                        "Part 3: Dose Expansion"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tocilizumab",
                    "description": "Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \\>/= 30 kg or at 12 mg/kg for participants \\< 30 kg.",
                    "armGroupLabels": [
                        "Part 1: RO7616789 QW: Dose Escalation",
                        "Part 2: RO7616789 Q3W: Dose Escalation",
                        "Part 3: Dose Expansion"
                    ],
                    "otherNames": [
                        "Actemra, RoActemra"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1, 2 and 3: Number of Participants with Adverse Events and Serious Adverse Events",
                    "description": "Adverse events were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0), and Cytokine release syndrome (CRS), will be graded based on the American Society for Transplantation and Cell Therapy (ASTCT) criteria.",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1 and 2: Number of Participants with Dose Limiting Toxicities (DLTs)",
                    "timeFrame": "Day 1 through Day 21 in cycle 1 (Cycle is 21 days)"
                },
                {
                    "measure": "Part 3: Objective Response Rate (ORR) as determined by Investigator",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 3: Disease Control Rates as Determined by the Investigator",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 3: Duration of Response (DOR) as Determined by the Investigator",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 3: Progression Free Survival (PFS) as Determined by the Investigator",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 3: Overall Survival (OS)",
                    "timeFrame": "Up to approximately 26 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1, 2 and 3: Serum Concentration of RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1, 2 and 3: Maximum Serum Concentration (Cmax) of RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1, 2 and 3: Area Under the Concentration-Time Curve (AUC) of RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1, 2 and 3: Total Clearance of RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1, 2 and 3: Terminal Half-Life of RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1, 2 and 3: Volume of Distribution of RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1, 2 and 3: Time to Reach Steady State Concentration of RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1, 2 and 3: Accumulation Ratio of RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1 and 2: ORR as Determined by the Investigators",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1 and 2: Disease Control Rates as Determined by the Investigator",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1 and 2: DOR as Determined by the Investigators",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1 and 2: PFS as Determined by the Investigators",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1 and 2: OS as Determined by the Investigators",
                    "timeFrame": "Up to approximately 26 months"
                },
                {
                    "measure": "Part 1, 2 and 3: Percentage of Participants With Anti-Drug Antibody (ADA) to RO7616789",
                    "timeFrame": "Up to approximately 26 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Life expectancy at least 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate hematologic and end organ function\n* Negative serum pregnancy test.\n* Adequate contraception and no or interruption of breastfeeding\n* Histologically confirmed extensive SCLC or poorly differentiated NEC of any other origin, relapsed after at least 1 systemic therapy\n* Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1\n* Confirmed availability of representative archival tumor specimens in formalin-fixed, paraffin-embedded (FFPE) blocks or unstained slides\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within 40 days after the final dose of study treatment\n* Poorly controlled Type 2 diabetes mellitus defined as a screening hemoglobin A1c \u2265 8% or a fasting plasma glucose \u2265 160 mg/dL (or 8.8 mmol/L)\n* QT interval corrected using Fridericia's formula (QTcF) \\> 470 ms. Abnormal electrocardiograms (ECGs) (triplicate) should be performed \\> 30 minutes apart\n* Current treatment with medications that are well known to prolong the QT interval\n* Prior treatment with anti-cluster of differentiation (CD)137 agents, anti-CD3 agents and/or delta-like ligand 3 (DLL3) targeted therapies\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 21 days prior to initiation of study treatment\n* Any history of an immune-related Grade 4 adverse event (AE) attributed to prior anti-programmed death ligand-1 (PD-L1) /PD-1 or anti-cytotoxic T-lymphocyte-associated protein (CTLA-4) therapy (other than asymptomatic elevation of serum amylase or lipase)\n* Any history of an immune-related Grade 3 adverse event attributed to prior anti-PD-L1 /PD-1 or anti-CTLA-4 therapy (other than asymptomatic elevation of serum amylase or lipase) that resulted in permanent discontinuation of the prior immunotherapeutic agent\n* History or clinical evidence of primary central nervous system (CNS) malignancy, symptomatic CNS metastases, CNS metastases requiring any anti-tumor treatment, or leptomeningeal disease and current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Spinal cord compression that has not been definitively treated with surgery and/or radiation\n* Active or history of clinically significant autoimmune disease\n* Positive test for human immunodeficiency virus (HIV) infection\n* Positive hepatitis B surface antigen (HbsAg) test, and/or positive total hepatitis B core antibody (HbcAb) test at screening\n* Prior allogeneic hematopoietic stem cell transplantation or prior solid organ transplantation\n* Administration of a live, attenuated vaccine within 4 weeks before first RO7616789 infusion\n* Known allergy or hypersensitivity to any component of the RO7616789 formulation",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Reference Study ID Number: BP44382 https://forpatients.roche.com/",
                    "role": "CONTACT",
                    "phone": "888-662-6728 (U.S. Only)",
                    "email": "global-roche-genentech-trials@gene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trials",
                    "affiliation": "Hoffmann-La Roche",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Georgetown Uni Medical Center; Lombardi Cancer Center",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20007",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "Massachusetts General Hospital;Oncology",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Henry Ford Hospital; Josephine Ford Cancer Center",
                    "status": "RECRUITING",
                    "city": "Detroit",
                    "state": "Michigan",
                    "zip": "48202-2689",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.33143,
                        "lon": -83.04575
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "John Theurer Cancer Center at Hackensack University Medical Center",
                    "status": "RECRUITING",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "11101",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "The Ohio State University Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "University of Pittsburgh Medical Center; Division of Hematology-Oncology",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "SCRI Oncology Partners",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030-4009",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Rigshospitalet; Fase 1 Enhed - Onkologi",
                    "status": "RECRUITING",
                    "city": "K\u00f8benhavn \u00d8",
                    "zip": "2100",
                    "country": "Denmark",
                    "geoPoint": {
                        "lat": 55.67594,
                        "lon": 12.56553
                    }
                },
                {
                    "facility": "National Cancer Center Hospital East; Thoracic Oncology",
                    "status": "RECRUITING",
                    "city": "Chiba",
                    "zip": "277-8577",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.6,
                        "lon": 140.11667
                    }
                },
                {
                    "facility": "National Cancer Center Hospital",
                    "status": "RECRUITING",
                    "city": "Tokyo",
                    "zip": "104-0045",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.6895,
                        "lon": 139.69171
                    }
                },
                {
                    "facility": "Uniwersyteckie Centrum Kliniczne; Osrodek Badan Wczesnych Faz",
                    "status": "RECRUITING",
                    "city": "Gda?sk",
                    "zip": "80-214",
                    "country": "Poland"
                },
                {
                    "facility": "Hospital Universitari Vall d'Hebron; Oncology",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Fundacion Jimenez Diaz; Servicio de Oncologia",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario 12 de Octubre; Servicio de Oncologia",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000055752",
                    "term": "Small Cell Lung Carcinoma"
                },
                {
                    "id": "D000018278",
                    "term": "Carcinoma, Neuroendocrine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28323",
                    "name": "Small Cell Lung Carcinoma",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20423",
                    "name": "Carcinoma, Neuroendocrine",
                    "asFound": "Neuroendocrine Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T5271",
                    "name": "Small Cell Lung Cancer",
                    "asFound": "Small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}